Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US-2019381297-A1 · Dec 19, 2019 · US
against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61 · Cooperative Patent Classification (CPC)
Chemical and metallurgical processes, compounds, and materials.
Related technology areas
Mapped technology topics for this CPC code.
| Metric | Value |
|---|---|
| CPC code | C07K16/2848 |
| Official title | {against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61} |
| Display label | against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61 |
| Total patents | 146 |
Filing trend
Year-over-year patent counts classified under this CPC code.
Filing activity over the last five years is rapidly declining.
| Year | Patents |
|---|---|
| 2015 | 9 |
| 2016 | 13 |
| 2017 | 14 |
| 2018 | 20 |
| 2019 | 12 |
| 2020 | 15 |
| 2021 | 18 |
| 2022 | 13 |
| 2023 | 12 |
| 2024 | 11 |
| 2025 | 7 |
| 2026 | 2 |
Representative patents
Representative publications under this CPC code from precomputed stats, or recent filings when stats are unavailable.
Disintegrin variants and pharmaceutical uses thereof
US-10508137-B2 · Dec 17, 2019 · US
Method of treating bone metastasis diseases, medicaments therefore, and a method of predicting the clinical outcome of treating bone metastasis diseases
US-10435472-B2 · Oct 8, 2019 · US
Anti-alpha-v integrin antibody for the treatment of prostate cancer
US-2019263913-A1 · Aug 29, 2019 · US
Methods and Compositions For the Treatment of Proteinuric Diseases
US-2018344803-A1 · Dec 6, 2018 · US
Milk fat globule epidermal growth factor 8 regulates fatty acid uptake
US-2018340027-A1 · Nov 29, 2018 · US
Sialylated Glycoproteins
US-2018327498-A1 · Nov 15, 2018 · US
Processable Single Chain Molecules and Polypeptides Made Using Same
US-2018320159-A1 · Nov 8, 2018 · US
Glycotargeting therapeutics
US-2018303951-A1 · Oct 25, 2018 · US
Library of antigen-binding molecules including modified antibody variable region
US-2018296668-A1 · Oct 18, 2018 · US
Diagnostic assays for supar-β3 integrin driven kidney diseases
US-2018284131-A1 · Oct 4, 2018 · US
Methods and compositions for treating and preventing disease associated with αvβ5 integrin
US-10087252-B2 · Oct 2, 2018 · US
Glycotargeting therapeutics
US-10046056-B2 · Aug 14, 2018 · US
Targeted coagulation factors and method of using the same
US-10035840-B2 · Jul 31, 2018 · US
Antibody targeting through a modular recognition domain
US-10030051-B2 · Jul 24, 2018 · US
Antibodies to tumor associated complex n-glycans with terminal glcnacbeta residues and methods of use thereof
US-2018193455-A1 · Jul 12, 2018 · US
Milk fat globule epidermal growth factor 8 regulates fatty acid uptake
US-10005838-B2 · Jun 26, 2018 · US
Compositions and methods for treatment and prevention of cardiovascular diseases
US-2018153993-A1 · Jun 7, 2018 · US
Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US-2018093084-A1 · Apr 5, 2018 · US
Polymeric Fc proteins and methods of screening to alter their functional characteristics
US-2018044416-A1 · Feb 15, 2018 · US
Frequently asked questions
Answers are generated from the same data shown on this page.
- What is CPC C07K16/2848?
- CPC C07K16/2848 is the Cooperative Patent Classification code for “against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61.”
- How many patents are filed under CPC C07K16/2848 (against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61)?
- Our database includes 146 publications tagged with this CPC code.
- Is patent activity under CPC C07K16/2848 growing?
- Publication counts under this code: 11 in 2024 vs 7 in 2025 (latest complete years).